Clinical protocol: phase I study of an adenovirus/prostate-specific antigen vaccine in men with metastatic prostate cancer.
Lubaroff
David M
DM
Department of Urology and Roland and Ruby Holden Cancer Research Laboratories, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA. david-lubaroff@uiowa.edu
Konety
Badrinath
B
Link
Brian K
BK
Ratliff
Timothy L
TL
Madsen
Tammy
T
Shannon
Mary
M
Ecklund
Dixie
D
Williams
Richard D
RD
D000256:Adenoviridae / Q000235:genetics; D019496:Cancer Vaccines / Q000009:adverse effects / Q000235:genetics / Q000627:therapeutic use*; D002985:Clinical Protocols; D017321:Clinical Trials, Phase I as Topic; D004306:Dose-Response Relationship, Immunologic; D005781:Gelatin Sponge, Absorbable; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D008297:Male; D018579:Patient Selection; D017430:Prostate-Specific Antigen / Q000235:genetics* / Q000276:immunology; D011471:Prostatic Neoplasms / Q000276:immunology / Q000473:pathology* / Q000628:therapy*
D019496:Cancer Vaccines; D017430:Prostate-Specific Antigen